ENTITY

Symbio Pharmaceuticals (4582 JP)

34
Analysis
Health CareJapan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
31 Oct 2024 20:00Issuer-paid

Symbio Pharmaceuticals (4582 JP): Q3 FY12/24 flash update

Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn. SG&A expenses increased by 12.7% YoY to...

Logo
137 Views
Share
02 Aug 2024 08:00Issuer-paid

Symbio Pharmaceuticals (4582 JP): 1H FY12/24 flash update

Sales decreased by 59.6% YoY to JPY1.3bn, with a gross profit of JPY996mn and a gross profit margin of 77.6%. Operating loss was JPY1.7bn,...

Logo
124 Views
Share
29 Apr 2022 23:25Issuer-paid

SymBio Pharmaceuticals - Termination of coverage

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ),...

Share
21 Jun 2021 17:43

Asia Shorts: Geely, Ganfeng, Pharmaron, Evergrande, Fujitsu, Canon, Renesas, Toshiba, LGD, Doosan

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
204 Views
Share
27 May 2021 14:28Issuer-paid

SymBio Pharmaceuticals - The first whole quarter of internal SymBio sales

SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the...

Share
x